Your browser doesn't support javascript.
loading
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
Cortés, Javier; Dieras, Véronique; Ro, Jungsil; Barriere, Jérôme; Bachelot, Thomas; Hurvitz, Sara; Le Rhun, Emilie; Espié, Marc; Kim, Sung-Bae; Schneeweiss, Andreas; Sohn, Joo Hyuk; Nabholtz, Jean-Marc; Kellokumpu-Lehtinen, Pirkko-Liisa; Taguchi, Julie; Piacentini, Federico; Ciruelos, Eva; Bono, Petri; Ould-Kaci, Mahmoud; Roux, Flavien; Joensuu, Heikki.
  • Cortés J; Vall d'Hebron Institute of Oncology, Barcelona, Spain and Ramon y Cajal University Hospital, Madrid, Spain. Electronic address: jacortes@vhio.net.
  • Dieras V; Institut Curie, Paris, France.
  • Ro J; National Cancer Center, Goyang-si, Republic of Korea.
  • Barriere J; Centre Antoine Lacassagne, Nice, France.
  • Bachelot T; Centre Léon Bérard, Lyon, France.
  • Hurvitz S; University of California, Los Angeles, CA, USA.
  • Le Rhun E; Centre Oscar Lambret, Lille, France; University Hospital, Lille, France.
  • Espié M; Hôpital Saint-Louis, Paris, France.
  • Kim SB; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Schneeweiss A; National Center for Tumor Diseases, University Hospital, Heidelberg, Germany.
  • Sohn JH; Severance Hospital, Sinchon-dong, Seodaemun-gu, Seoul, South Korea.
  • Nabholtz JM; Centre Jean Perrin, Clermont-Ferrand, France.
  • Kellokumpu-Lehtinen PL; Tampere University Hospital and University of Tampere, Tampere, Finland.
  • Taguchi J; Sansum Clinic, Santa Barbara, CA, USA.
  • Piacentini F; Università di Modena e Reggio Emilia, Modena, Italy.
  • Ciruelos E; Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Bono P; Comprehensive Cancer Center, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland.
  • Ould-Kaci M; Boehringer Ingelheim, Paris, France.
  • Roux F; Boehringer Ingelheim, Reims, France.
  • Joensuu H; Comprehensive Cancer Center, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland.
Lancet Oncol ; 16(16): 1700-10, 2015 Dec.
Article en En | MEDLINE | ID: mdl-26596672
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Quinazolinas / Vinblastina / Neoplasias Encefálicas / Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Receptor ErbB-2 / Inhibidores de Proteínas Quinasas / Antineoplásicos Fitogénicos Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies País como asunto: America do norte / Asia / Europa Idioma: En Año: 2015 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Quinazolinas / Vinblastina / Neoplasias Encefálicas / Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Receptor ErbB-2 / Inhibidores de Proteínas Quinasas / Antineoplásicos Fitogénicos Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies País como asunto: America do norte / Asia / Europa Idioma: En Año: 2015 Tipo del documento: Article